Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.本文提供包含N-乙醯基精胺酸且當與缺乏N-乙醯基精胺酸之調配物相比時具有降低之黏度的PCSK9結合多肽調配物,諸如包含依伏庫單抗(evolocumab)之彼等調配物。本文亦提供調配該等組合物之方法,該等方法為有利的,因為其保存某些組分。該等包含PCSK9結合多肽之調配物可投與至患者以治療及/或預防PCSK9相關疾病、病狀及病症。